A large amt of data has emerged on multiple promising ADCs for lung cancer in recent months, with several agents on the precipice of approval. For a concise & comprehensive review of ADCs, see our latest review in Clin Adv Hem Onc. Benjamin Levy Samuel Rosner

2/ We report the final data analysis of the safety, ORR, PFS, & OS of the phase I patients & 7 expansion cohorts (N=120) in this investigator-initiated, multicenter, phase I trial of #CaboNivo doublet, & #CaboNivoIpi triplet + expansion cohorts: NCT02496208

Retrospective look at impact of durvalumab on pneumonitis after chemoradiation for NSCLC Clinical Lung Cancer. With durva, 57% G1 pneumonitis, 38% G2, 5% G3. Steroid course 17w with durva and 7w without. Pneumonitis relapse 23% with durvalumab, 7% without. clinical-lung-cancer.com/article/S1525-…

Real world data on QTc prolongation with osimertinib Clinical Lung Cancer. 970 pts with #EGFR NSCLC & pre/post EKGs: 0.9% had G3 QTc prolongation (median onset d49) with no arrhythmic events; most had baseline QTc>450. Rechallenge better with dose reduction. clinical-lung-cancer.com/article/S1525-…

Can we predict risk of immune related toxicity with immunotherapy for NSCLC? Report Clinical Lung Cancer showed 15.2% rate of high-grade irAEs overall (esp respiratory and GI) with higher risk seen with mutations in MYC, TEK, FANCA, FAM123B, MET. clinical-lung-cancer.com/article/S1525-…

Sunday brunch with my former mentor at NIH, now a friend, Dr. Udayan Guha. We had a nice conversation about drug development, AI, kids, and life! The clinical trial we worked on together when I was a fellow is about to be submitted. Clinical research takes a long time.

Survived 15 hours of flight and arrived in Korea! Thanks to my wonderful colleagues Stephen V Liu, MD Joshua Reuss who are covering for me so that I can spend time with family.

A section about systemic therapy for NSCLC from Harrison’s Principles of Internal Medicine, 16th edition, 2005, a textbook I used to read as a medical student. The only non-chemo option mentioned is gefitinib. The rest is history. The field has come a long way.

Real world outcomes with chemotherapy for pts who progress after PACIFIC regimen (durvalumab after chemoradiation for stage III NSCLC) Clinical Lung Cancer. Platinum based chemotherapy had PFS 13.2m if durvalumab PFS ≥1y but only 4.7m if durva PFS < 1y. clinical-lung-cancer.com/article/S1525-…

Unplugged. Family time in Gangneung, S. Korea.

More on RBM10 and NSCLC at Clinical Lung Cancer. Associated with worse prognosis (PFS 6.7m vs 13.9m) and with TP53 co-mutation, more likely to have rapid progression. Recall RBM10 seen in residual disease after neoadjuvant EGFR TKI in work from Collin Blakely MD, PhD. clinical-lung-cancer.com/article/S1525-…

Dr. Chul Kim from Georgetown Lombardi will discuss advances in treating lung cancer with an #EGFR exon 20 or a #HER2 exon 20 mutation at #DCLung24. Join us Saturday, October 19th in downtown Washington, DC for this IASLC endorsed, one-day #CME meeting! medstarhealth.org/dclung24

Explore a multicenter real-world analysis highlighting the clinical activity of combined MET and EGFR inhibition in NSCLC after EGFR inhibitor therapy, suggesting that true MET amplification, rather than polysomy, is associated with clinical benefit. bit.ly/4di4pHT

🔥Impact of Durvalumab on the Duration and Complexity of Corticosteroid Therapy for Pneumonitis After Chemoradiotherapy 🎙️Dr. Saori Murata Hidehito HORINOUCHI Clinical Lung Cancer 🎯Duration📈 🎯Complexity of tapering patterns📈 #LCSM OncoAlert clinical-lung-cancer.com/article/S1525-…

Returning from a vacation in Korea, feeling recharged! Memories that I will cherish for a long time were created Grateful for the time spent with family and friends.

Can an electronic medical record (EMR) alert really increase uptake of lung cancer screening? Report Clinical Lung Cancer shows screening increased from 2.2% of eligible patients to 21.1% with higher rates for age ≥ 65 (25.8%) vs younger (15.6%). clinical-lung-cancer.com/article/S1525-…

Join us at #DCLung24 on Saturday, October 19, 2024 for a one-day, CME and MOC, IASLC-endorsed, multi-disciplinary meeting with all of the latest updates on diagnosis and management of lung cancer from these all-star faculty! Hope to see you there! medstarhealth.org/dclung24

Looking forward to discussing the latest updates in small cell lung cancer at the ASCO Direct Meeting!

Happy to announce that I officially started my new faculty position with Dana-Farber's Lowe Center for Thoracic Oncology at Dana-Farber and Harvard Medical School! I am honored and thrilled to join the team. 🫁⭐️⚕️ #lcsm #NewBeginnings

While amylase & lipase elevation often seen in trials of targeted agents, actual clinical pancreatitis is uncommon. In this retrospective report Clinical Lung Cancer from Drs. Meyer May-Lucie Mihaela Aldea and team, incidence of clinical pancreatitis was .08%! clinical-lung-cancer.com/article/S1525-…